The FDA has issued a warning letter to Empower Clinic Services LLC, which does business as Empower Pharmacy, alleging that its high-volume compounded GLP-1 formulations are essentially copies of FDA-approved drugs. The letter, dated September 18, 2026, takes aim at the practice of adding vitamins to compounded semaglutide and tirzepatide to differentiate them from approved products.
According to the agency, Empower’s addition of cyanocobalamin to compounded semaglutide and niacinamide to compounded tirzepatide amounts to a “pretextual” difference — a change the FDA says was made to appear distinct from approved drugs without, in the agency’s view, a genuine medical rationale. Legal analyses published in early October 2026 by ArentFox Schiff and AMC Defense Law confirmed this is the first known instance of FDA using that specific characterization in a compounding GLP-1 enforcement letter.
The letter raises a second, separate category of concerns: alleged insanitary conditions at the company’s Houston facility that the agency says could contaminate drugs with filth.
What happened
FDA’s warning letter to Empower Pharmacy, dated September 18, 2026, contains two distinct sets of allegations.
First, the agency cited insanitary conditions at the Houston facility that it says could result in drug contamination. Second, FDA alleged that Empower’s compounded GLP-1 products — semaglutide with added cyanocobalamin and tirzepatide with added niacinamide — are copies of commercially available, FDA-approved drugs. Under Section 503A of the Food, Drug, and Cosmetic Act, compounded drugs that are essentially copies of approved products fall outside the statutory exemptions that allow traditional compounding.
FDA characterized the vitamin additions as “pretextual” differences — changes the agency views as designed to avoid the copy prohibition rather than to serve a genuine clinical purpose. Legal analyses published October 3–5, 2026 by the law firms ArentFox Schiff and AMC Defense Law described this framing as a novel FDA enforcement theory, noting it is the first known use of the word “pretextual” in a compounding GLP-1 enforcement letter.
A warning letter is an enforcement action, not a final ruling. Empower has 15 working days to respond to the agency.
Why it matters
The “pretextual difference” characterization matters because vitamin-added GLP-1 formulations have been a key legal justification for mass-market compounded semaglutide and tirzepatide distributed through telehealth platforms. If FDA applies this standard more broadly, the primary legal basis for high-volume GLP-1 compounding could weaken significantly.
The affected groups include telehealth platforms prescribing compounded GLP-1 drugs, 503A compounding pharmacies that add vitamins to GLP-1 formulations, consumers using compounded semaglutide or tirzepatide with vitamin additives, and healthcare attorneys advising compounding clients.
It is important to note that the allegations in the letter have not been adjudicated. The “pretextual” standard is an FDA enforcement position, not a court ruling, and its durability as a legal standard remains to be tested.
What to watch next
- Empower Pharmacy’s response within the 15-working-day window and any subsequent FDA escalation, such as seizure, injunction, or further enforcement action.
- Whether FDA applies the “pretextual” characterization to warning letters against other compounders, which would signal a broader enforcement posture.
- How telehealth platforms that rely on vitamin-added compounded GLP-1s respond — whether by reformulating, changing suppliers, or exiting the compounded GLP-1 market.
- Whether the “pretextual difference” theory is tested in court, where its legal viability would ultimately be determined.
Sources
Industry information only. Not medical or legal advice.
